The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

The latest announcement is out from Merck & Company ( (MRK) ).

Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...